Research programme: TLR9 antagonists - PfizerAlternative Names: TLR9 antagonists - Pfizer
Latest Information Update: 13 Aug 2009
At a glance
- Originator Coley Pharmaceutical Group
- Class Small molecules
- Mechanism of Action Toll-like receptor 9 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Oct 2004 Preclinical trials in Autoimmune disorders in USA (unspecified route)